Form 4 Filing for Aligos Therapeutics, Inc. - Insider Transaction

This filing details a Form 4 submission for Aligos Therapeutics, Inc. (ALGS) concerning an insider transaction. James Paul Scopa, a director, was granted 5,860 stock options on June 25, 2026. These options, with an exercise price of $5.50, are set to vest on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027, contingent upon continuous service. The options are exercisable into 5,860 shares of Common Stock. The transaction was reported on June 29, 2026.